Group 1 - The core viewpoint of the article highlights that Valiant Bio-B (09887) has seen a significant stock increase of over 8%, currently trading at 64.75 HKD with a transaction volume of 44.92 million HKD [1] - Valiant Bio announced that its dual-specific antibody LBL-034, developed on the TCE technology platform LeadsBody, has received Fast Track designation from the FDA for the treatment of relapsed/refractory multiple myeloma [1] - Huafu Securities released a report stating that Valiant Bio is comprehensively laying out next-generation tumor immunotherapy based on its agonist platform, TCE platform, and ADC, with a focus on "technology platform + innovative targets" [1] Group 2 - The company has consistently developed its technology platforms since 2015 with the X-body platform, followed by the LeadsBody platform in 2016, and has accumulated expertise in dual and tri-antibody technologies [1] - Valiant Bio's pipeline covers cutting-edge areas such as immune checkpoints and multi-specific antibodies, aiming to create a differentiated product line [1]
港股异动 维立志博-B(09887)再涨超8% TCE双抗LBL-034获FDA快速通道资格认定